CareDx Study Links Elevated AlloSure Kidney Levels to Nearly Threefold Higher Risk of Adverse Graft Outcomes

By Public Technologies
  • CareDx is presenting AlloSure Kidney study results at ASN Kidney Week in Denver, October 22-25, 2026.
  • Elevated AlloSure Kidney levels were associated with greater risk of graft loss or declining kidney function in patients with borderline rejection or T-cell-mediated rejection.
  • An independent randomized trial found AlloSure-based monitoring reduced kidney transplant biopsies while maintaining similar clinical outcomes.
  • A multinational validation study found AlloSure Kidney and AlloSure Plus maintained strong rejection prediction under updated Banff 2024 pathology criteria.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CareDx Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610220705BIZWIRE_USPR_____20261022_BW386659) on October 22, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk